Late Breaking Abstract - Nintedanib for Lymphangioleiomyomatosis: an open-label phase II study - Milan 2023

Challenges and novelties in rare interstitial lung diseases

Chair(s): Maria Molina Molina, Cormac McCarthy

Session type: Oral presentation

Late Breaking Abstract - Nintedanib for Lymphangioleiomyomatosis: an open-label phase II study

Sergio Alfonso Harari

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Nintedanib for Lymphangioleiomyomatosis: an open-label phase II study

Sergio Alfonso Harari

Replay

Poster

Abstract

Slides

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) in Greece: 20 years in progress

Effrosyni D. Manali

Replay

Abstract

Slides

Preclinical studies supporting a first-in-human trial of pulmonary macrophage transplantation therapy of CSF2RA-associaited PAP

Bruce Trapnell

Replay

Abstract

Slides

Exploring the prognosis and pathogenesis of secondary pulmonary alveolar proteinosis

Haruyuki Ishii

Replay

Poster

Abstract

Slides

New diagnostic approaches for lymphangioleiomyomatosis (LAM)

Christoph Lederer

Replay

Poster

Abstract

Slides

Alveolar fibroblast activation and epithelial injury/repair in pulmonary lymphangioleiomyomatosis (LAM)

Vera Krymskaya

Replay

Poster

Abstract

Slides

Phenotypic characterization of interstitial lung disease associated with mutations in SFTPC and ABCA3 in adults

Remi Diesler

Replay

Poster

Abstract

Slides

Reversal of interstitial lung disease after olipudase alfa enzyme replacement therapy in adults with acid sphingomyelinase deficiency

Francesco Bonella

Replay

Poster

Abstract

Slides

Pirfenidone in post-covid19 pulmonary fibrosis (FIBRO-COVID): Phase-II randomized clinical trial (NCT04607928)

Guadalupe Bermudo Peloche

Replay

Poster

Abstract

Slides

Home spirometry in regular care for patients with pulmonary fibrosis

Gizal Nakshbandi

Replay

Poster

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}